Therapeutic efficacy of FASN inhibition in preclinical models of HCC,Hepatology

当前位置： X-MOL 学术 › Hepatology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Therapeutic efficacy of FASN inhibition in preclinical models of HCC
Hepatology ( IF 12.9 ) Pub Date : 2022-01-25 , DOI: 10.1002/hep.32359
Haichuan Wang _{1,

2,

3} , Yi Zhou _{3,

4} , Hongwei Xu _{1,

2,

3} , Xue Wang ₅ , Yi Zhang _{3,

6} , Runze Shang ₃ , Marie O'Farrell ₇ , Stephanie Roessler ₈ , Carsten Sticht ₉ , Andreas Stahl ₅ , Matthias Evert ₁₀ , Diego F Calvisi ₁₀ , Yong Zeng _{1,

2} , Xin Chen ₃

Affiliation

Liver Transplantation Division, Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China.
Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California, USA.
Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, PR China.
Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California, USA.
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
3-V Biosciences, Menlo Park, California, USA.
Institute of Pathology, Heidelberg University, Heidelberg, Germany.
NGS Core Facility, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
Institute of Pathology, University of Regensburg, Regensburg, Germany.

Aberrant activation of fatty acid synthase (FASN) is a major metabolic event during the development of HCC. We evaluated the therapeutic efficacy of TVB3664, a FASN inhibitor, either alone or in combination, for HCC treatment.

中文翻译：